Mebendazole

規格

31431-39-7CAS番号

250-635-4EC番号

methyl N-(6-benzoyl-1H-benzimidazol-2-yl)carbamateIUPAC名

C16H13N3O3化学式

295.29 g/mol分子量

mebendazole; 31431-39-7; Vermox; Pantelmin; Telmin; Mebenvet; Ovitelmin; Vermicidin; Vermirax; MBDZ; Verpanyl; Besantin; Noverme; Mebendazolum; Mebendazol; Methyl 5-benzoyl-2-benzimidazolecarbamate; 5-Benzoyl-2-benzimidazolecarbamic acid methyl ester; Emverm; methyl N-(6-benzoyl-1H-benzimidazol-2-yl)carbamate; Carbamic acid, (5-benzoyl-1H-benzimidazol-2-yl)-, methyl ester; Methyl 5-benzoyl-2-benzimidazolylcarbamate; Zhihuanqing; R 17,635; Methyl 5-benzoyl benzimidazole-2-carbamate; R 17635; DTXSID4040682; (5-Benzoyl-1H-benzimidazol-2-yl)-carbamic acid methyl ester; methyl N-(6-benzoyl-1H-1,3-benzodiazol-2-yl)carbamate; NSC 184849; NSC-184849; 2-Benzimidazolecarbamic acid, 5-benzoyl-, methyl ester; R-17635; 81G6I5V05I; NSC184849; CHEBI:6704; DTXCID2020682; Anti Worm; mebendazolo; Telmintic; Telmintic Powder; Telmin Equine Wormer; Telmin Syringe Formula; RefChem:5986; P02CA01; 250-635-4; K-6451; NSC-5618; Bantenol; Mebenoazole; Mebutar; Lomper; Methyl (5-benzoyl-1H-benzo[d]imidazol-2-yl)carbamate; C16H13N3O3; MFCD00057872; CCRIS 4479; methyl (5-benzoyl-1H-benzimidazol-2-yl)carbamate; Methyl N-(5-benzoyl-1H-benzimidazol-2-yl)carbamate; Sufil; CHEMBL685; N-2 (5-Benzoyl-benzimidazole) carbamate de methyle; N-(Benzoyl-5, benzimidazolyl)-2, carbamate de methyle; Carbamic acid, N-(5-benzoylbenzimidazol-2-yl)-, methyl ester; Versid; Equivurm Plus; Methyl 6-benzoyl-1H-benzimidazol-2-ylcarbamate; 5-Benzoyl-2-benzimidazolecarbamic acid, methyl ester; MMV003152; NCGC00016806-01; (5-Benzoyl-1H-benzimidazol-2-yl)carbamic acid methyl ester; Mebex; CAS-31431-39-7; Mebendazol [INN-Spanish]; Mebendazolum [INN-Latin]; Vermox (TN); Methyl (6-benzoyl-1H-benzo[d]imidazol-2-yl)carbamate; methyl [5-(phenylcarbonyl)-1H-benzimidazol-2-yl]carbamate; SMR000036734; HSDB 3232; SR-01000003109; EINECS 250-635-4; Methyl N-(5-benzoyl-2-benzimidazolyl)carbamate; Mebatreat; Mebendazole (JAN/USP/INN); UNII-81G6I5V05I; Equivurmp Plus; Mebenoazole;; Vermicidin;; Ovitelmin;; Pantelmin;; Bantenol;; Besantin;; Mebendazole RS; Mebenvet;; Vermirax;; Mebendazole CRS; Mebutar;; Noverme;; Equivurm Plus;; Lomper;; Telmin;; Vermox;; N-2 (5-Benzoyl-benzimidazole) carbamate de methyle [French]; Mebex;; N-(Benzoyl-5, benzimidazolyl)-2, carbamate de methyle [French]; V95; Prestwick_310; Mebendazole; 4030; Mebendazole [USAN:USP:INN:BAN:JAN]; Mebendazole (Standard); Spectrum_001298; CPD000036734; MBDZ;; Prestwick0_000217; Prestwick1_000217; Prestwick2_000217; Prestwick3_000217; Spectrum2_001401; Spectrum3_001439; Spectrum4_000416; Spectrum5_001381; MEBENDAZOLE [INN]; MEBENDAZOLE [JAN]; MEBENDAZOLE [HSDB]; MEBENDAZOLE [USAN]; Probes1_000013; Probes2_000149; MEBENDAZOLE [VANDF]; Cambridge id 5250893; Methyl [5-(Benzoyl)benzimidazol-2-yl]carbamate; TimTec1_000869; MEBENDAZOLE [MART.]; Oprea1_278237; Oprea1_768530; SCHEMBL15860; BSPBio_000233; BSPBio_003178; CBDivE_010559; KBioGR_000712; KBioSS_001778; MEBENDAZOLE [USP-RS]; MEBENDAZOLE [WHO-DD]; MEBENDAZOLE [WHO-IP]; MLS000028491; MLS006011879; BIDD:GT0087; DivK1c_000751; MEBENDAZOLUM [WHO-IP]; SCHEMBL536464; SPECTRUM1501110; SPBio_001442; SPBio_002154; BPBio1_000257; orb1309581; orb3025371; MEBENDAZOLE [GREEN BOOK]; SCHEMBL29390263; SCHEMBL29409261; GTPL13427; HMS502F13; KBio1_000751; KBio2_001778; KBio2_004346; KBio2_006914; KBio3_002398; MEBENDAZOLE [ORANGE BOOK]; MSK5546; NINDS_000751; 2-Benzimidazolecarbamic acid, 5-benzoyl-, methyl ester (8CI); GLXC-08108; HMS1536H11; HMS1568L15; HMS1921F03; HMS2090B03; HMS2092B15; HMS2095L15; HMS3259B11; HMS3604N11; HMS3712L15; HMS5083F21; MEBENDAZOLE [EP MONOGRAPH]; MEBENDAZOLE [USP IMPURITY]; N-(6-benzoyl-1H-benzimidazol-2-yl)carbamic acid methyl ester; Pharmakon1600-01501110; MEBENDAZOLE [USP MONOGRAPH]; MSK5546-400DM; Tox21_110620; BBL008298; BDBM50180753; CCG-39628; EBC-00598; EBC-47476; HY-17595R; NSC757838; s4610; SBB057003; STK093862; AKOS000539066; AKOS015896232; Carbamic acid, (5-benzoyl-1H-benzimidazol-2-yl)-, methyl ester (9CI); Mebendazole for system suitability CRS; Tox21_110620_1; CS-3974; DB00643; FM25020; NC00639; NSC-757838; IDI1_000751; NCGC00016806-02; NCGC00016806-03; NCGC00016806-04; NCGC00016806-05; NCGC00016806-06; NCGC00016806-07; NCGC00016806-08; NCGC00016806-09; NCGC00016806-10; NCGC00016806-12; NCGC00016806-13; NCGC00016806-15; NCGC00016806-16; NCGC00021698-03; NCGC00021698-04; NCGC00021698-05; NCGC00021698-06; NCGC00021698-07; AC-12064; AS-12272; DA-65310; HY-17595; ST011967; SY051142; SBI-0051641.P002; AB00052203; M1605; M2273; NS00008616; EN300-50844; D00368; D70118; AB00052203-09; AB00052203_10; Mebendazole, VETRANAL(TM), analytical standard; AG-205/04588045; F219242; Mebendazole Solution in DMSO/Methanol, 400ug/mL; Mebendazole, analytical standard, >=98% (HPLC); Q422194; SR-01000003109-2; SR-01000003109-3; BRD-K77987382-001-01-7; BRD-K77987382-001-06-6; BRD-K77987382-001-08-2; BRD-K77987382-001-13-2; SR-01000003109-10; Methyl (5-benzoyl-1H-1,3-benzimidazol-2-yl)carbamate; Z234895185; Mebendazole Working Standard (Secondary Reference Standard); Mebendazole, European Pharmacopoeia (EP) Reference Standard; methoxy-N-[5-(phenylcarbonyl)benzimidazol-2-yl]carboxamide; methoxy-N-[6-(phenylcarbonyl)benzimidazol-2-yl]carboxamide; Mebendazole, United States Pharmacopeia (USP) Reference Standard; Mebendazole for system suitability, European Pharmacopoeia (EP) Reference Standard別名